Fig. 3

Patient clinical outcomes for Biqi and LEF group in the ITT analysis. These include a patient response rates for ACR20, ACR50, ACR70, b patient response rates for EULAR good or moderate response, c proportion of patients with reported adverse events, and d patient clinical measurements at baseline, 4, 12 and 24 weeks. Paired Wilcoxon test was performed followed by Benjamin-Hochberg (BH) post hoc correction for multiple comparisons on clinical measures and in between timepoints. The FDR-adjusted P-values between 24 weeks and baseline were reported. *** FDR P < 0.001, ** P < 0.01, * P < 0.05